RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
for cardiovascular disease in hemodialysis patients.
Circulation 86: 475-482, 1992
741. Kuboyama M, Ageta M, Ishihara T, Fujiura Y, Kashio N,
Ikushima I. Serum lipoprotein(a) concentration and Apo(a)
isoform under the condition of renal dysfunction. J
Atheroscler Thromb 10: 283-289, 2003
742. Samuelsson O, Attman P-O, Knight-Gibson C, Kron B,
Larsson R, Mulec H, y cols. Lipoprotein abnormalities
without hyperlipidemia in moderate renal inssuficiency.
Nephrol Dial Transplant 9: 1580-1585, 1994
743. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary
heart disease. Metaanalysis of prospective studies.
Circulation 102: 1082-1085, 2000
744. Kovesdy CP, Astor BC, Longenecker JC, Coresh J. Association
of kidney function with serum lipoprotein(a) level: the third
National Health and Nutrition Examination Survey (1991-
1994). Am J Kidney Dis 40: 899-908, 2002
745. Attman PO, Samuelsson O, Johansson AC, y cols. Dialysis
modalities and dyslipidemia. Kidney Int 63(suppl 84): S110-
S112, 2003
746. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie
M, Lacour B y cols. Incidence and risk factors of atherosclerotic
cardiovascular accidents in predialysis chronic renal
failure patients. A prospective study. Nephrol Dial Transplant
12: 2597-2602, 1997
747. Landrat MJ Thambyrajah J, Mc Glynn FJ, Jones HJ, Baigent C,
Kendall MJ y cols. Epidemiological evaluation of known and
suspected cardiovascular risk factors in chronic renal impairment.
Am J Kidney Dis 38: 537-546, 2001
748. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA.
Cardiac risk factors and the use of cardioprotective medications
in patients with chronic renal insufficiency. Am J
Kidney Dis 37: 484-489, 2001
749. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J
y cols. Cardiovascular disease in patients with chronic kidney
disease: Getting to the heart of the matter. Am J Kidney
Dis 38: 1398-1407, 2001
750. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A,
Sherrard DJ y cols. HMG-CoA reductase inhibitors are associated
with reduced mortality in ESRD patients. Kidney Int
61: 297-304, 2002
751. Control de la Colesterolemia en España, 2000. Un instrumento
para la prevención cardiovascular. Ministerio de
Sanidad y Consumo. Madrid 2000.
752. Gutiérrez-Fuentes JA, Gómez-Gerique J, Gómez de la
Cámara A, Rubio MA, García A, Arístegui I. Dieta y riesgo
cardiovascular en España (DRECE II). Descripción de la evolución
del perfil cardiovascular. Med Clin (Barc) 115: 726-
729, 2000
753. Wood D, de Backer G, Faergeman O, Graham I, Mancia G,
Pyorala K y cols. Prevention of coronary heart disease in clinical
practice. Recommendations of the Second Joint Task
Force of European and others Societies on Coronary
Prevention. Eur Heart J 19: 1434-1503, 1998
754. Expert Panel on Detection Evaluation and Treatment of High
Blood Cholesterol in Adults: Executive Summary of the Third
Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation and Treatment
of High Blood Cholesterol in Adults (Adult Treatment panel
III). JAMA 285: 2486-2497, 2001
755. European Guidelines on cardiovascular disease prevention
in clinical practice. Third Joint Task Force of European and
other Societies on Cardiovascular Disease Prevention in
Clinical Practice. European Journal of Cardiovascular
Prevention and Rehabilitation 10 (suppl 1): S1-S78, 2003
756. Genest J, Frohlich J, Fodor G, McPherson R (the Working
Group on Hypercholesterolemia and other dyslipidemias).
Recommendations for the management of dyslipidemia and
the prevention of cardiovascular disease: summary of the
2003 update. CMAJ 169: 921-924, 2003
757. Harmonized Clinical Guidelines on Prevention of
Atherosclerotic Vascular Disease. International Atherosclerosis
Society. http//www.athero.org
758. The Expert Panel: Report of the national cholesterol education
program expert panel on detection, evaluation and treatment
of high blood cholesterol in adults. Arch Intern Med
148: 36-69, 1998
759. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas
JM, Castelli WP y cols. Effects of age, gender, and menopausal
status on plasma low density lipoprotein cholesterol and
apolipoprotein B levels in the Framingham Offspring Study. J
Lipid Res 35: 779-792, 1994
760. Wanner C. Importance of hyperlipidaemia and therapy in
renal patients. Nephrol Dial Transplant 15(suppl5): 92-96,
2000
761. Joven J, Villabona C, Vilella E. Pattern of hyperlipoproteinemia
in human nephrotic syndrome: influence of renal failure
and diabetes mellitus. Nephron 64: 565-569, 1993
762. Uhlig K, Levey A, Sarnak M. Traditional cardiac factors in
individuals chronic kidney disease. Semin Dialysis 16: 118-
127, 2003
763. Tonelli M, Moyé L, Sacks F, Kiberd B, Curhan G; Cholesterol
and Recurrent Events (CARE) Trial Investigators. Pravastatin
for secondary prevention of cardiovascular events in persons
with mild chronic renal insufficiency. Ann Intern Med
138:98-104, 2003
764. Tonelli M, Moyé L, Sacks F, Cole T, Curhan GC; Cholesterol
and Recurrent Events Trial Investigators. Effect of Pravastatin
on loss of renal function in people with moderate chronic
renal insufficiency and cardiovascular disease. J Am Soc
Nephrol 14: 1605-1613, 2003
765. Jungst D, Caselmann H, Kutschera P, Weisweiler P. Relation
of hyperlipidemia in serum and loss of high density lipoproteins
in urine in the nephrotic syndrome. Clin Chim Acta
168: 159-167, 1987
766. Takegoshi T, Kitoh C, Haba T, Hirai J, Wakasugi T, Saga T y
cols. A study of the clinical significance of lipoprotein(a) in
nephrotic síndrome. Jpn J Med 30: 21-25, 1991
767. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin
synthesis, albuminuria and hyperlipemia in nephrotic
patients. Kidney Int 31. 1368-1376, 1987
768. Joven J, Rubiés-Prat J, Espinel E, Ras MR, Piera L. High density
lipoproteins in untreated idiopathic nephrotic síndrome without
renal failure. Nephrol Dial Transplant 2: 149-153, 1987
769. Clemens MR, Bursa-Zanetti Z. Lipid abnormalities and peroxidation
of erythrocytes in nephrotic syndrome. Nephron 53:
325-329, 1989
770. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C,
Thillet J. Elevated lipoprotein (a) levels in primary nephrotic
syndrome. Am J Kidney Dis 22: 808-813, 1993
771. Attman PO, Nyberg G, William-Olsson T, Knight-Gibson C,
Alaupovic P. Dyslipoproteinemia in diabetic renal failure.
Kidney Int 42: 1381-1389, 1992
210